The German Amphotericin B market participants observed prices to be stable in September 2025, as it was in the previous months. It is backed by steady demand from pharma and healthcare industries as well as adequate supply availability. China, being the biggest exporting country of APIs such as Amphotericin B, is still determining global prices, and stable trends in the U.S. market are likely to influence Germany. Freight trends also alleviated cost pressures with the Peak Season Surcharge (PSS) pushed back to October 15 and the September 15 General Rate Increase (GRI) completely axed. Carriers reduced rates and pushed them out until mid-October as demand was subdued, bringing relief to importers. While inclement weather and possible port congestion in China poses a threat, it likely won’t affect Germany's supply-demand balance in the near term. Analysts predict prices to start creeping upwards in the fourth quarter of 2025 as a result of seasonal demand and logistical reconfigurations, yet for September, steadiness is the overriding concern.
Key Highlights:
The German Amphotericin B market is expected to be price stable until September 2025, based on the trend observed for the past few months. Market players credit persistent Amphotericin B demand from downstream pharmaceutical and healthcare industries and sufficient supply levels as the driving force for this stability.
China, the world’s largest exporter of active pharmaceutical ingredients (APIs) including Amphotericin B, continues to play a central role in shaping global prices. Prices of Amphotericin B over the past few weeks have been quite stable, and this is going to impact the German market, with Amphotericin B traders and distributors looking for low volatility in the coming days.
Shipping and logistics have also contributed to this relatively calm pricing environment of Amphotericin B. The Peak Season Surcharge (PSS), which often adds cost pressure in the run-up to Golden Week in Asia, has been postponed until October 15. With market demand softening, no PSS was introduced for the pre-holiday period this year. Similarly, the September 15 General Rate Increase (GRI) was fully withdrawn, as carriers responded to muted booking activity by lowering freight charges to secure volume. Several major shipping companies have extended their current rate structures until October 14, further alleviating cost pressures along global supply chains.
These developments have eased concerns among German importers who had feared higher freight rates could filter into pharmaceutical costs. On the contrary, the decline in freight prices has created a supportive backdrop for stability in Amphotericin B pricing. Market insiders note that supply in Germany remains ample, with sufficient Amphotericin B stockpiles to meet domestic requirements.
Meanwhile, in China, unsettled weather conditions are adding an element of caution to supply chain planning. The wake of previous typhoon-enforced shutdowns, followed by the threat of another tropical storm on September 18-20, mounts the possibility of short-term port disruption. Nevertheless, with current balance between demand and supply, these occurrences should not be expected to put much pressure on German market prices in the immediate term.
Later this quarter, experts predict German Amphotericin B prices may start rising in the last quarter of 2025. With the seasonal demand resuming upward after the rise and freight adjustments hopefully resuming after midmonth October, a slow rise beckons. For September, though, the consensus remains clear: Amphotericin B prices are set to hold steady, providing much-needed predictability to pharmaceutical stakeholders across the German market.
